Lv4
700 积分 2024-05-08 加入
Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma
21天前
已完结
Longitudinal Flow Cytometry Identified "Minimal Residual Disease" (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma
29天前
已关闭
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
1个月前
已完结
Will Survival Improve By Treating Multiple Myeloma Patients at MRD Relapse? the Remnant Study
4个月前
已完结
Will Survival Improve By Treating Multiple Myeloma Patients at MRD Relapse? the Remnant Study
4个月前
已关闭
The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China
5个月前
已完结
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
5个月前
已完结
Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS
5个月前
已完结
Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view
5个月前
已关闭
Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment
5个月前
已完结
皖公网安备34019202002308
